Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | CTSL | P07711 | 2/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.41 |
| ▸ | TSHR | P16473 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27231928 | 0.94 | SYK (0.53) | SYKSMN1; SMN2CTSLCTSBCTSS | |
| SCHEMBL1073539 | 0.86 | CYP3A4 (0.46) | SMN1; SMN2CTSLCTSBCTSSCYP3A4 | |
| SCHEMBL31454371 | 0.86 | SYK (0.53) | SYKSMN1; SMN2CTSLCTSBCTSS | |
| SCHEMBL10152374 | 0.86 | SYK (0.48) | SYKSMN1; SMN2CTSLCTSBCTSS | |
| SCHEMBL6130356 | 0.86 | CA12 (0.46) | SMN1; SMN2CTSSDPP8DPP9ALDH1A1 | |
| SCHEMBL23460475 | 0.83 | SYK (0.47) | SYKSMN1; SMN2CTSLCTSSDPP8 | |
| SCHEMBL1074213 | 0.82 | CYP3A4 (0.43) | SMN1; SMN2CTSLCTSBCTSSCYP3A4 | |
| SCHEMBL2394536 | 0.79 | SYK (0.51) | SYKSMN1; SMN2CTSLCTSBCTSS | |
| SCHEMBL6887697 | 0.79 | AKT1 (0.43) | CTSLCTSBCTSSDPP8DPP9 | |
| SCHEMBL31360840 | 0.77 | SYK (0.43) | SYKSMN1; SMN2CTSLCTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1389181-A4 | ANTIOXIDANT NITROXIDES AND NITRONES AS THERAPEUTIC AGENTS | PANORAMA RES INC (US) | 2005-10-19 | — | — | EP | disclosed |
| US-6852889-B2 | Antioxidant nitroxides and nitrones as therapeutic agents | PANORAMA RESEARCH, INC. (US) | 2005-02-08 | — | — | US | disclosed |
| US-20040186320-A1 | Alpha-phenyl-N-(7-tert-butoxycarbonylamino-3,5-dialkyl -adamantane)nitrones; treating disorders resulting from overproduction of nitric oxide and other free radicals such as neurological, neuropsychiatric and inflammatory disorders | WANG YUQIANG (US) | 2004-09-23 | — | — | US | disclosed |
| US-6717012-B2 | SUCH AS ALPHA-PHENYL-N-(7-TERT-BUTOXYCARBONYLAMINO-3,5-DIMETHYLADAMANTANE)NITRONE FOR TREATMENT OF NEUROLOGICAL/ INFLAMMATORY DIORDERS, AND AGING, WHICH RESULT FROM THE OVERPRODUCTION OF NITRIC OXIDE | NEUROMOLECULAR, INC. | 2004-04-06 | — | — | US | disclosed |
| EP-1389181-A2 | ANTIOXIDANT NITROXIDES AND NITRONES AS THERAPEUTIC AGENTS | PANORAMA RESEARCH, INC. (US) | 2004-02-18 | — | — | EP | disclosed |
| US-20030045574-A1 | Antioxidant nitroxides and nitrones as therapeutic agents | PANORAMA RESEARCH, INC. | 2003-03-06 | — | — | US | disclosed |
| WO-2002078615-A2 | ANTIOXIDANT NITROXIDES AND NITRONES AS THERAPEUTIC AGENTS | PANORAMA RESEARCH, INC. (US) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186320-A1 | Alpha-phenyl-N-(7-tert-butoxycarbonylamino-3,5-dialkyl -adamantane)nitrones; treating disorders resulting from overproduction of nitric oxide and other free radicals such as neurological, neuropsychiatric and inflammatory disorders | NOS1, NOS3, NOS2 | SYK 2161/4885SMN1; SMN2 1295/4885CTSL 883/4885 |
| US-20030045574-A1 | Antioxidant nitroxides and nitrones as therapeutic agents | NOS3, NOX3, NOX1 | SYK 2059/4885SMN1; SMN2 474/4885CTSL 1674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.